International audienceT-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies, with high tumor heterogeneity and poor prognosis. More than 60% of TALL patients carry NOTCH1 gene mutations, leading to abnormal expression of downstream target genes and aberrant activation of various signaling pathways. We found that chidamide, an HDAC inhibitor, exerts an antitumor effect on TALL cell lines and primary cells including an anti-NOTCH1 activity. In particular, chidamide inhibits the NOTCH1-MYC signaling axis by down-regulating the level of the intracellular form of NOTCH1 (NICD1) as well as MYC, partly through their ubiquitination and degradation by the proteasome pathway. We also report here the preli...
The Notch signaling pathway is activated in the majority of T cell acute lymphoblastic leukemias (T-...
Pancreatic cancer is a fatal malignancy worldwide and urgently requires valid therapies. Previous re...
Notch pathway signaling is implicated in several human cancers. Aberrant activation and mutations of...
International audienceT-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hemat...
Histone deacetylases (HDACs) are enzymes involved in the remodeling of chromatin. In recent years, i...
Chidamide, a histone deacetylase (HDAC) inhibitor, displays antitumor activities in different tumor ...
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Although the therapy of ...
T-acute lymphoblastic leukemia (T-ALL) is characterized by several genetic alterations and poor prog...
Abstract Background Many conventional chemotherapeutic drugs are known to be involved in DNA damage,...
Abstract Rituximab/chemotherapy relapsed and refractory B cell lymphoma patients have a poor overall...
The identification of SERCA (sarco/endoplasmic reticulum calcium ATPase) as a target for modulating ...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological tumor resulting from the ...
The identification of activating mutations in NOTCH1 in over 50 % of T-cell acute lymphoblastic leuk...
International audienceSeveral studies have revealed that endosomal sorting controls the steady-state...
Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia (T-ALL), mortality ...
The Notch signaling pathway is activated in the majority of T cell acute lymphoblastic leukemias (T-...
Pancreatic cancer is a fatal malignancy worldwide and urgently requires valid therapies. Previous re...
Notch pathway signaling is implicated in several human cancers. Aberrant activation and mutations of...
International audienceT-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hemat...
Histone deacetylases (HDACs) are enzymes involved in the remodeling of chromatin. In recent years, i...
Chidamide, a histone deacetylase (HDAC) inhibitor, displays antitumor activities in different tumor ...
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Although the therapy of ...
T-acute lymphoblastic leukemia (T-ALL) is characterized by several genetic alterations and poor prog...
Abstract Background Many conventional chemotherapeutic drugs are known to be involved in DNA damage,...
Abstract Rituximab/chemotherapy relapsed and refractory B cell lymphoma patients have a poor overall...
The identification of SERCA (sarco/endoplasmic reticulum calcium ATPase) as a target for modulating ...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological tumor resulting from the ...
The identification of activating mutations in NOTCH1 in over 50 % of T-cell acute lymphoblastic leuk...
International audienceSeveral studies have revealed that endosomal sorting controls the steady-state...
Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia (T-ALL), mortality ...
The Notch signaling pathway is activated in the majority of T cell acute lymphoblastic leukemias (T-...
Pancreatic cancer is a fatal malignancy worldwide and urgently requires valid therapies. Previous re...
Notch pathway signaling is implicated in several human cancers. Aberrant activation and mutations of...